mTOR inhibitors have shown clinical activity in patients with advanced breast cancer [54,55] and are being actively investigated in this setting in combination with other agents that have shown clinical activity in metastatic breast cancer (MBC). The gene discussed is MTOR; the disease is breast cancer.